39 results about "Membranous nephropathy" patented technology

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

The invention discloses a super-paramagnetic iron oxide nanoparticle compound as well as a preparation method and application thereof. The super-paramagnetic iron oxide nanoparticle compound is prepared by the following steps: preparing super-paramagnetic iron oxide nanoparticles by taking Fe3O4 with surface modified with a polyethylene glycol derivative as a core; and then modifying an IL-1 antibody on the surfaces of the super-paramagnetic iron oxide nanoparticles, so that the super-paramagnetic iron oxide nanoparticle compound is prepared. The super-paramagnetic iron oxide nanoparticle compound prepared by the invention can achieve specific affinity with high-expression IL-1 in mesangial area and glomerular area of chronic glomerulonephritis in vivo and can display and quantify the early lesions of the chronic glomerulonephritis in the forms of magnetic resonance images and data; therefore, the super-paramagnetic iron oxide nanoparticle compound can be used for the early diagnosis of diseases and for the dynamic monitoring of changes of nephropathy, and a magnetic resonance molecular imaging means for noninvasive and in vivo evaluation of membranous nephropathy is provided.

The invention provides a heterocyclic compound containing piperidine as shown in a formula (I). The compounds are used for treating diseases and diseases related to complement alternative pathway activation, such as paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN) including C3 glomerulopathy (C3G), membranous nephropathy (MN) and other glomerular diseases, atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), diabetic retinopathy (DR), and other diseases associated with abnormal activation of the alternative complement pathway by inhibiting/regulating a complement factor B.

The invention provides a method for detecting a biological sample. The method comprises the following steps: (1) separating the biological sample collected from a subject to obtain a sample to be detected; and (2) detecting one or more of IgG4, PLA2R, Nephrin and NPHS2 in the sample to be detected, and adopting the obtained detection result as a preliminary basis for judging that whether the subject needs renal biopsy or not. The detection method can be used to perform primary screening on membranous nephropathy, and provides reference data for whether renal biopsy puncture in the later stageis performed or not; and the detection method is noninvasive, and has the advantages of simplicity in operation and low detection cost.

The invention discloses a traditional Chinese medicine mixture for treating the pediatric membranous nephropathy. The traditional Chinese medicine holds that the pediatric membranous nephropathy belongs to the 'edema' range and relates to the lung, spleen and kidney three-viscera malfunction. Most of the pediatric membranous nephropathy is mainly characterized by insufficiency of both the spleen and the kidney, blood stasis obstructing the collaterals and internal stagnation of fluid-dampness. The operations of treating the root and strengthening the body resistance serve as the principal, and the operations of warming kidney and eliminating damp are assisted on the basis of invigorating spleen, supplementing qi and invigorating the circulation of blood. Therefore, the traditional Chinesemedicine mixture for treating the pediatric membranous nephropathy is prepared from the following traditional Chinese medicines of plantain seed, semen coicis, rust-coloured crotalaria herb with root, herba lycopi, the root of bidentate achyranthes, rhizoma sparganii, astragalus mongholicus, boschniakia rossica, herba epimedii, rhizoma polygonati and rhizoma atractylodis, wherein the traditional Chinese medicines have the efficacy on tonifying Qi, lifting yang, removing blood stasis, and inducing diuresis to alleviate edema. The obtained traditional Chinese medicine mixture is taken by patients. According to the clinical test of our hospital, the total effective rate of the traditional Chinese medicine mixture is 93.3%, and a treatment group is obviously superior to a control group on theaspects of lowering cholesterol (CHOL) and urine protein and improving albumin (ALB) and clinic efficiency.

The invention relates to a traditional Chinese medicinal composition for treating membranous nephropathy and a method for preparing the traditional Chinese medicinal composition for treating the membranous nephropathy. The traditional Chinese medicinal composition is prepared from the following raw materials in proportions by weight: 60 to 120 parts of radix astragali seu hedysari, 15 to 30 parts of radix rehmanniae recens, 15 to 30 parts of radix rehmanniae preparata, 15 to 30 parts of gorgon fruit, 15 to 30 parts of Chinese pyrola herb, 30 to 90 parts of rhizoma smilacis glabrae, 30 to 90 parts of herba hedyotidis diffusae, 15 to 30 parts of radix salviae miltiorrhizae, 0.5 to 3 parts of hirudo recens, 6 to 12 parts of herba schizonepetae and 6 to 12 parts of radix saposhnikoviae. The raw materials are extracted according to a certain technical method, and then are made, together with pharmaceutically acceptable accessories, into a traditional Chinese medicinal oral preparation. The traditional Chinese medicinal composition which is provided by the invention has the effects of tonifying spleen and kidney, supplementing qi, nourishing yin, removing dampness through diuresis and promoting blood circulation, and is used for treating various kinds of acute and chronic nephritis, and proteinuria and edema which are caused by a nephrotic syndrome.

The invention provides a method, system and device for predicting membranous nephropathy based on machine learning, and the method comprises the steps: data collection, data preprocessing, feature screening, prediction model construction, and prediction model testing and evaluation: obtaining the data information of a to-be-retrieved patient, inputting the data information of the to-be-retrieved patient into a prediction model, and carrying out the prediction of membranous nephropathy. The prediction model predicts the membranous nephropathy according to the data information of the patient to be retrieved, in a word, the prediction model for membranous nephropathy can be developed and verified by using a machine learning method, high-efficiency and high-accuracy prediction can be realized, and the method has important research significance and use value for early treatment and prevention of membranous nephropathy.

The invention discloses a traditional Chinese medicine preparation for treating membranous nephropathy. The traditional Chinese medicine preparation is prepared from angelica sinensis, prepared rehmannia root, ligusticum wallichii, parched white peony root, fructus psoraleae, teasel root, eucommia ulmoides, wolfberry fruits, herba epimedii, astragalus membranaceus, rhizoma curculiginis, rhizoma drynariae, cordyceps sinensis, fructus alpiniae oxyphyllae, cynomorium songaricum, amethyst, odobenus rosmarus, salvia miltiorrhiza, sargent gloryvine, dandelion, honeysuckle, lophatherum gracile, glossy privet fruits, mulberries and dogwood according to a certain weight ratio. The traditional Chinese medicine preparation has the efficacies of tonifying the liver and kidneys, tonifying the kidneys, invigorating yang, boosting essence and filling marrow, and is significant in treatment effect.

The invention discloses a traditional Chinese medicine preparation for treatment of membranous nephropathy. The traditional Chinese medicine preparation comprises, by weight, 10-30 parts of cortex magnoliae officinalis, 5-20 parts of cherokee rose, 10-35 parts of indian buead, 5-25 parts of large head atractylodes rhizome, 5-10 parts of flower of Japanese camellia, 5-15 parts of fortune eupatorium herb, 10-35 parts of radix astragali, 10-25 parts of dwarf lilyturf tuber, 10-20 parts of semen plantaginis, 5-25 parts of common andrographis herb, 5-25 parts of white Chinese peony root, 10-25 parts of mosla scabra, 10-20 parts of cortex eucommiae, 5-25 parts of all-grass of desertliving cistanche, 5-20 parts of stir-fried Chinese yam, 5-15 parts of nippon hawthorn fruit, 5-25 parts of danshen root, 5-15 parts of prepared rhizome of adhesive rehmannia, 5-15 parts of lalang grass rhizome, 15-20 parts of oriental waterplantain rhizome and 5-20 parts of caulis perillae. The traditional Chinese medicine preparation special for treating membranous nephropathy is free of toxic and side effects and has functions of curing, caring and nourishing kidney. As components of the traditional Chinese medicine preparation are supplementary to each other, therapeutic effect is improved while curative ratio is increased.

The invention discloses a new application of selepravastatin, namely an application of selepravastatin in preparation of a medicine for treating nephropathy. The application has the advantages that anew medicine for treating the nephropathy is provided, the effect of treating the membranous nephropathy is achieved through the immune effect, and finally animal experiments prove that the selaprivapeptide can reduce total urinary protein, urinary albumin and systolic pressure of membranous nephropathy model animals, so that the selaprivapeptide is a new immune agent and a novel therapeutic meansfor treating the membranous nephropathy.

A traditional Chinese medicine composition for treating membranous nephropathy, belonging to the technical field of membranous nephropathy treatment, comprising 5-10 parts of raw astragalus, 0.5-1 part of whole worm, 2-4 parts of fenugreek, and 3 parts of chuanxiong in terms of parts by mass. ‑5 parts, Zhi Licorice 2‑3 parts. The usage method of the traditional Chinese medicine composition is also disclosed. The traditional Chinese medicine composition mainly strengthens the spleen and kidney, activates blood and removes dampness, and attacks toxins and dredges collaterals. To treat membranous nephropathy, combined with the use method of the traditional Chinese medicine composition, the therapeutic effect is remarkable without any side effects.

The present disclosure provides methods for treating lupus nephritis in an individual having lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the disclosure provides methods for treating membranous nephropathy.

Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

The present disclosure provides a polypeptide and method for treating and/or preventing nephrotic syndrome, such as but not limited to those associated with minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

The invention discloses markers for judging the curative effect of clinical treatment on membranous nephropathy. The group of markers includes TCR V beta 13, specifically, when the total use frequencyof a V gene in a sample is counted, if the percentage of the use frequency of the TCR V beta 13 is greater than 0.046%, it is predicted that the clinical treatment has a curative effect on membranousnephropathy. The TCR V beta 13 in a TCR coding gene of a patient is taken as a marker, if the use frequency of TCR V beta 13 is greater than 0.046%, it can be predicted that the clinical treatment has the curative effect on the patient with membranous nephropathy, it is predicted that after the clinical treatment, a qualitative experiment of urine protein shows a negative result, the AUC of thismethod is 0.80, when a threshold is set to 0.046%, sensitivity is 0.75, and specificity is 0.728.